Key result
TMEM43 S358L mutation promotes ARVC cardiac fibrosis by hyperactivating NF-κB to drive TGFβ1 expression.
Why the study?
The Ser358Leu mutation of TMEM43 is commonly identified in patients with a highly lethal ARVD subtype, but the underlying mechanism of ARVD development is not fully understood.
The TMEM43 S358L mutation promotes arrhythmogenic right ventricular dysplasia/cardiomyopathy pathogenesis by hyper-activating the NF-κB-TGFβ signal cascade, leading to cardiac fibrosis and adipogenesis.
TMEM43 S358L mice may enable ARVD5 mechanism studies; leaves open human translation and therapeutic relevance.
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a genetic cardiac muscle disease that accounts for approximately 30% sudden cardiac death in young adults. The Ser358Leu mutation of transmembrane protein 43 (TMEM43) was commonly identified in the patients of highly lethal and fully penetrant ARVD subtype, ARVD5. Here, we generated TMEM43 S358L mouse to explore the underlying mechanism. This mouse strain showed the classic pathologies of ARVD patients, including structural abnormalities and cardiac fibrofatty. TMEM43 S358L mutation led to hyper-activated nuclear factor κB (NF-κB) activation in heart tissues and primary cardiomyocyte cells. Importantly, this hyper activation of NF-κB directly drove the expression of pro-fibrotic gene, transforming growth factor beta (TGFβ1), and enhanced downstream signal, indicating that TMEM43 S358L mutation up-regulates NF-κB-TGFβ signal cascade during ARVD cardiac fibrosis. Our study partially reveals the regulatory mechanism of ARVD development.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2018) studied Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). TMEM43 S358L mutation vs. Wild type (WT) was evaluated on Cardiac fibrosis and NF-κB-TGFβ signal cascade activation. The TMEM43 S358L mutation promotes cardiac fibrosis in arrhythmogenic right ventricular dysplasia/cardiomyopathy by hyper-activating NF-κB, which directly drives TGFβ1 expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: